Stock Events

Stock Events

Kaleido Biosciences

$0.000100

10

+$0.00+0% Wednesday 20:00

Statistics

Day High

0.0001

Day Low

0.0001

52W High

0.01

52W Low

0.0001

Volume

1,055

Avg. Volume

1,785

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

22NovExpected

Q2 2022

Q3 2022

Q4 2022

Q4 2022

Q1 2024

Q2 2024

Q3 2024

-0.51

-0.34

-0.17

0

Expected EPS

N/A

Actual EPS

N/A

Financials

-8,178.26%Profit Margin

Unprofitable

2017

2018

2019

2020

2021

1.1MRevenue

-90.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KLDO. It's not an investment recommendation.

SoFi Technologies

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Synlogic operates in the synthetic biology field focusing on developing therapeutics to improve the gut microbiome, similar to Kaleido's focus on microbiome metabolic therapies.

Seres Therapeutics is directly competing in the microbiome therapeutic space, developing a similar range of products aimed at modifying the microbiome to treat diseases.

REGENXBIO is involved in gene therapy but its interest in developing treatments that could intersect with microbiome health places it as a competitor.

Seres Therapeutics

Seres Therapeutics, under ticker MCRB, is focused on microbiome therapeutics for multiple conditions, directly competing with Kaleido's approach to disease treatment.

Axsome Therapeutics

Axsome Therapeutics, while primarily focused on CNS disorders, its broad approach to novel therapies could see it venturing into microbiome-related treatments.

Amgen, a large biotech firm, has a broad interest in innovative therapeutic areas, including potential interest in the microbiome, making it a competitor due to its size and resources.

About

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.

Show more...

CEO

Dr. Mark A. Wingertzahn Ph.D.

Employees

76

Country

United States

ISIN

US4833471000

Listings

0 Comments

Share your thoughts

FAQ

What is Kaleido Biosciences stock price today?▼

The current price of KLDO is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Kaleido Biosciences stock price performance more closely on the chart.

What is Kaleido Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Kaleido Biosciences stocks are traded under the ticker KLDO.

Is Kaleido Biosciences stock price growing?▼

KLDO stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Kaleido Biosciences has showed a +0% increase.

What is Kaleido Biosciences revenue for the last year?▼

Kaleido Biosciences revenue for the last year amounts to 1.1M USD.

What is Kaleido Biosciences net income for the last year?▼

KLDO net income for the last year is -90.29M USD.

How many employees does Kaleido Biosciences have?▼

As of July 11, 2026, the company has 76 employees.

In which sector is Kaleido Biosciences located?▼

Kaleido Biosciences operates in the Health & Wellness sector.

When did Kaleido Biosciences complete a stock split?▼

Kaleido Biosciences has not had any recent stock splits.

Where is Kaleido Biosciences headquartered?▼

Kaleido Biosciences is headquartered in Lexington, United States.